Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione

Lyso-7 is a novel synthetic thiazolidinedione, which is a receptor (pan) agonist of PPAR α,β/δ,γ with anti-inflammatory activity. We investigated the cardiotoxicity of free Lyso-7 in vitro (4.5-450 nM), and Lyso-7 loaded in polylactic acid nanocapsules (NC) in vivo (Lyso-7-NC, 1.6 mg/kg). In previou...

Full description

Saved in:
Bibliographic Details
Main Authors: Giani M. Garcia (Author), Jérôme Roy (Author), Ivan R. Pitta (Author), Dulcinéia S. P. Abdalla (Author), Andrea Grabe-Guimarães (Author), Vanessa C. F. Mosqueira (Author), Sylvain Richard (Author)
Format: Book
Published: MDPI AG, 2021-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b584e5f5538e4f4f9a16e6e13cc3c58d
042 |a dc 
100 1 0 |a Giani M. Garcia  |e author 
700 1 0 |a Jérôme Roy  |e author 
700 1 0 |a Ivan R. Pitta  |e author 
700 1 0 |a Dulcinéia S. P. Abdalla  |e author 
700 1 0 |a Andrea Grabe-Guimarães  |e author 
700 1 0 |a Vanessa C. F. Mosqueira  |e author 
700 1 0 |a Sylvain Richard  |e author 
245 0 0 |a Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione 
260 |b MDPI AG,   |c 2021-09-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13091521 
500 |a 1999-4923 
520 |a Lyso-7 is a novel synthetic thiazolidinedione, which is a receptor (pan) agonist of PPAR α,β/δ,γ with anti-inflammatory activity. We investigated the cardiotoxicity of free Lyso-7 in vitro (4.5-450 nM), and Lyso-7 loaded in polylactic acid nanocapsules (NC) in vivo (Lyso-7-NC, 1.6 mg/kg). In previous work, we characterized Lyso-7-NC. We administered intravenously Lyso-7, Lyso-7-NC, control, and blank-NC once a day for seven days in mice. We assessed cell contraction and intracellular Ca<sup>2+</sup> transients on single mice cardiomyocytes enzymatically isolated. Lyso-7 reduced cell contraction and accelerated relaxation while lowering diastolic Ca<sup>2+</sup> and reducing Ca<sup>2+</sup> transient amplitude. Lyso-7 also promoted abnormal ectopic diastolic Ca<sup>2+</sup> events, which isoproterenol dramatically enhanced. Incorporation of Lyso-7 in NC attenuated drug effects on cell contraction and prevented its impact on relaxation, diastolic Ca<sup>2+</sup>, Ca<sup>2+</sup> transient amplitude, Ca<sup>2+</sup> transient decay kinetics, and promotion of diastolic Ca<sup>2+</sup> events. Acute effects of Lyso-7 on cardiomyocytes in vitro at high concentrations (450 nM) were globally similar to those observed after repeated administration in vivo. In conclusion, we show evidence for off-target effects of Lyso-7, seen during acute exposure of cardiomyocytes to high concentrations and after repeated treatment in mice. Nano-encapsulation of Lyso-7 in polymeric NC attenuated the unwanted effects, particularly ectopic Ca<sup>2+</sup> events known to support life-threatening arrhythmias favored by stress or exercise. 
546 |a EN 
690 |a peroxisome proliferator-activated receptor-γ 
690 |a cardiotoxicity 
690 |a metabolic syndrome 
690 |a atherosclerosis 
690 |a contraction 
690 |a calcium transient 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 9, p 1521 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/9/1521 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/b584e5f5538e4f4f9a16e6e13cc3c58d  |z Connect to this object online.